Mycosis Fungoides
📧 Sign up to get email alerts when something new happens for Mycosis Fungoides.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-05-14Clinical Trial Update: T Cell Repertoire Analysis of Immune Mediated Skin Diseases
The document reports a completed clinical trial update analyzing T cell repertoires in immune-mediated skin diseases, focusing on psoriasis …
-
CLINICAL_TRIALS withdrawal · 2025-05-02Clinical Trial Update: Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma [Phase 1]
A Phase 1 trial evaluating reduced-intensity conditioning before a partially matched donor stem cell transplant for advanced cutaneous T-cel…
-
CLINICAL_TRIALS withdrawal · 2025-04-29Clinical Trial Update: Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides [Phase 2]
A Phase 2 trial evaluating low-dose total skin electron beam radiation therapy with mechlorethamine hydrochloride gel for Mycosis Fungoides …
-
CLINICAL_TRIALS research · 2025-03-28Clinical Trial Update: Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
A clinical trial is evaluating low-dose total skin electron therapy for patients with refractory or relapsed stage IB–IIIA mycosis fungoides…
-
CLINICAL_TRIALS research · 2025-03-10Clinical Trial Update: Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.
This clinical trial is recruiting to evaluate predictive and prognostic biomarkers in patients with Mycosis fungoides and Sézary syndrome.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-01-21FDA Approved: POTELIGEO — Supplemental Application (Kyowa Kirin, Inc.)
FDA approved a supplemental application for POTELIGEO (mogamulizumab-kpkc) submitted by Kyowa Kirin, Inc., as part of the drug's regulatory …
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
A completed clinical trial investigated the role of large extracellular vesicles as biomarkers in various lymphomas and lymphoproliferative …
-
CLINICAL_TRIALS trial_result · 2025-01-17Clinical Trial Update: Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas [Phase 1]
Phase 1 trial update evaluating the combination of romidepsin and parsaclisib for relapsed or refractory T-cell lymphomas; the study status …
-
EMA approval · 2024-12-12EMA Authorised: Ledaga (chlormethine) — Helsinn Birex Pharmaceuticals Ltd.
The European Medicines Agency authorised Ledaga (chlormethine) for the treatment of mycosis fungoides, with orphan designation noted.
-
CLINICAL_TRIALS research · 2024-12-09Clinical Trial Update: A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab in combination with radiotherapy for relapsed, refractory cutaneous T-cell lymphoma, speci…
-
CLINICAL_TRIALS research · 2024-11-08Clinical Trial Update: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma [Phase 2]
A Phase 2 clinical trial of IPH4102 (lacutamab) alone or in combination with chemotherapy is evaluating advanced T-cell lymphomas, including…
-
CLINICAL_TRIALS research · 2024-10-21Clinical Trial Update: Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study
Prospective multicenter study evaluating flow cytometry detection of the KIR3DL2 marker for diagnosing Sézary syndrome, assessing therapeuti…
-
CLINICAL_TRIALS research · 2024-09-04Clinical Trial Update: Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)
Real-world observational study PROSPER evaluating mogamulizumab (Poteligeo) in adults with mycosis fungoides and Sézary syndrome; the study …
-
CLINICAL_TRIALS trial_result · 2024-08-30Clinical Trial Update: Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) [Phase 2]
Phase 2 trial evaluating maintenance treatment with resminostat in patients with advanced mycosis fungoides or Sézary syndrome has completed…
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas [Phase 1, Phase 2]
This clinical trial update covers a Phase 1/2 study of pembrolizumab plus pralatrexate in relapsed or refractory peripheral T-cell lymphomas…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides [Phase 1, Phase 2]
Phase 1/2 study of mogamulizumab in combination with extracorporeal photopheresis for Sezary syndrome and mycosis fungoides was terminated.
-
FDA approval · 2024-08-07FDA Approved: LYMPHIR — Original Application (Citius Pharmaceuticals, Inc.)
FDA approved LYMPHIR (denileukin diftitox-CXDL) through an original application for the treatment of CD25-expressing cutaneous T-cell lympho…
-
CLINICAL_TRIALS research · 2024-05-31Clinical Trial Update: A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
This clinical trial is investigating molecular-subtyping-based therapeutic strategies for Cutaneous T-cell Lymphoma and is currently recruit…
-
CLINICAL_TRIALS trial_result · 2024-05-22Clinical Trial Update: Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides [NA]
This trial evaluated biodynamic imaging to predict response to gemcitabine in cutaneous T-cell lymphoma (mycosis fungoides); the study was t…
-
CLINICAL_TRIALS research · 2024-05-20Clinical Trial Update: The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients
An update on a clinical trial investigating the mechanism of action of chlormethine gel in adults with Mycosis Fungoides (MF-CTCL), with rec…
-
CLINICAL_TRIALS research · 2024-05-01Clinical Trial Update: Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis
This clinical trial update discusses the investigation of allogeneic hematopoietic stem cell transplantation for epidermotropic cutaneous T-…
-
FDA approval · 2024-03-06FDA Approved: BEXAROTENE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for bexarotene from Mylan Pharmaceuticals Inc., marking regulatory approval of the supplemental subm…
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma [Phase 2]
Phase 2 trial update reporting pharmacokinetics and ECG determinations after 8 weeks of HyBryte treatment in Cutaneous T-Cell Lymphoma/Mycos…
-
CLINICAL_TRIALS trial_result · 2023-06-05Clinical Trial Update: Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides [Phase 2]
Phase II study of AFM13 in relapsed/refractory CD30-positive T-cell lymphoma and transformed mycosis fungoides completed with results posted…
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL [Phase 3]
Phase 3 clinical trial of naloxone hydrochloride for relief of pruritus in patients with cutaneous T-cell lymphoma (Mycosis Fungoides and Sé…